BridgeBio Pharma Adds $125M
Palo Alto-based BridgeBio Pharma, a biopharmaceuticals developer focused on genetic diseases, said on Wednesday that it has raised $135M in a funding round. The funding was led by Viking Global Investors and KKR, and also included Perceptive Advisors, AIG, Aisling Capital, Cormorant Capital and Janus Funds. The firm said the funding goes to both existing and new programs. Neil Kumar, Ph.D. is the company's co-founder and CEO.
posted on Wednesday, September 13, 2017
Related companies:
BridgeBio
Related stories:
> Eidos Therapeutics Prices IPO, To Debut Today
> Circle Pharma Ups Funding To $6.5M
> SuccessFactors Files For $125M IPO
> Asenqua Ventures Raises $125M Fund (UPDATE)
> Confluent Finds $125M
silicontap.com Home